Wall Street Wire
BiomX’s Phase 2b Trial Initiation: The Dawn of a Phage Therapy Revolution
Under the Radar Phage Therapy Trailblazer Begins Next Chapter in Fight Against Antibiotic-Resistant Infections
Wall Street Wire
Sponsored company news and issuer-paid coverage. Wall Street Wire articles are paid promotional content; see each article’s disclaimer.
Wall Street Wire
Nuvectis Pharma’s NXP900 Clears Key Hurdle Boosting Potential as Key Combination Therapy in Multi Billion Dollar NSCLC Market
New study reveals Nuvectis Pharma’s NXP900 to be safe to use with CYP3A, the enzyme pathway through which many leading NSCLC therapies are metabolized; NXP900 could be come the ideal combination therapy with market-leading treatments
Wall Street Wire
Wall Street Analysts Think PolyPid, a $35M BioPharma Player is Significantly Undervalued, Here’s Why
In the competitive landscape of biotechnology investments, discovering undervalued opportunities with significant upside potential requires careful analysis of clinical milestones, market positioning, and Wall Street sentiment. PolyPid Ltd. (NASDAQ: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has recently captured the attention of industry analysts following breakthrough
Wall Street Wire
The $4.1 Trillion Healthcare Revolution: How DarioHealth Could Rewrite the Rules of Chronic Disease Management
Imagine a world where managing multiple chronic conditions isn’t a nightmare of fragmented care, endless appointments, and mounting medical bills. This isn’t a futuristic fantasy, it’s the vision of DarioHealth Corp. (NASDAQ: DRIO)*, a digital health company that’s quietly building what could be the most comprehensive
Wall Street Wire
With Fresh Funding and Strong Phase 3 Data, PolyPid Advances Towards FDA Approval
Surgical infection prevention breakthrough demonstrates 58% infection reduction as company secures funding through regulatory approval
Wall Street Wire
Israel’s Silent Killer in the Sky—and the $15 Million Micro-Cap To Watch: Duke Robotics’ Stock Rockets 65 % as Demand for Drone Tech Soars
Rumours have swirled for months about a new drone quietly used in Israel’s most volatile flash‑points—small enough to launch from a backpack, yet lethal enough to end a firefight with a single, precisely aimed burst. The Israel Defense Forces will not confirm the platform’s identity, but
Wall Street Wire
America’s Air Traffic Meltdown: Newark’s Blackout Puts Infrastructure Risk in the Spotlight—And One Small-Cap Could Be Uniquely Positioned
For 90 seconds on a late April morning, one of the busiest airports in America went dark. Air traffic controllers at Newark Liberty International Airport lost radar and radio contact with every plane in the sky. No communication. No visibility. Just 90 long seconds of silence in a highly coordinated
Wall Street Wire
PolyPid Just Delivered Game-Changing Phase 3 Topline Results, and Wall Street Thinks it Massively Undervalued
Breakthrough Phase 3 topline data released today shows 58% reduction in surgical infections as analysts maintain $11-$13 price targets on $2.89 stock
Wall Street Wire
Wall Street Sees 3,000% Upside as This $13M Biotech Tackles Medicine’s Superbug Crisis (PHGE)
BiomX Inc. (NYSE: PHGE)* has achieved something that eluded Big Pharma for decades—successful clinical trials using viruses to treat life-threatening infections that no longer respond to antibiotics. With positive Phase 2 results showing statistically significant healing in diabetic foot bone infections (a condition so challenging no new drugs
Wall Street Wire
PolyPid Receives Buy Rating and $11 Price Target: Analyst Sees 300%+ Upside Potential Ahead of Pivotal Phase 3 Data
H.C. Wainwright has initiated coverage of PolyPid Ltd. (NASDAQ: PYPD)* with a Buy rating and an $11 price target, representing potential upside of nearly 300% from current trading levels around $2.80 per share. The bullish outlook comes as the late-stage biotech company approaches a potentially transformative topline
Wall Street Wire
Silexion Therapeutics: The Next Potential Blockbuster in Cancer’s Last Untamed Frontier?
Silexion Therapeutics* stands at the cutting edge of cancer’s final frontier – the notorious KRAS mutation that drives some of medicine’s deadliest tumors. Their groundbreaking SIL-204 therapy isn’t just showing promise; it’s delivering jaw-dropping results with 50% tumor reduction and complete destruction in half of
Wall Street Wire
Actelis Networks Q1 2025: Strengthened Balance Sheet, Improved Margins, and Global Expansion Underscore Growth Potential
Actelis Networks (NASDAQ: ASNS)* demonstrated solid progress in Q1 2025, maintaining stable quarterly revenue while significantly improving gross margins to 35% (up from 30% in Q1 2024) and reducing net loss per share by 56% year-over-year. The company has successfully strengthened its balance sheet with shareholders’ equity reaching